2-氰基-N-丙基乙酰胺 | 52493-35-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氰基-N-丙基乙酰胺
• 英文名称: 2-cyano-N-propylacetamide
• 英文别名: cyanoacetic acid propylamide；2-cyano-N-propyl-acetamide；N1-propyl-2-cyanoacetamide；N-n-propyl cyanoacetamide；N-propyl-2-cyanoacetamide；N-propylcyanoacetamide
• CAS: 52493-35-3
• 化学式: C₆H₁₀N₂O
• mdl: MFCD02176952
• 分子量: 126.158
• InChiKey: QXWFLDZVDBAJAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2926909090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-氰基-N-丙基乙酰胺 在 盐酸 、 aluminum (III) chloride 、 溶剂黄146 、 sodium nitrite 作用下， 以 水 、 甲苯 为溶剂， 生成 4-氨基-8-溴-N-丙基氮杂嗪-3-胺
  参考文献：
  名称：

  Development and SAR of functionally selective allosteric modulators of GABAA receptors

  摘要：

  Positive modulators at the benzodiazepine site of alpha 2- and alpha 3-containing GABA(A) receptors are believed to be anxiolytic. Through oocyte voltage clamp studies, we have discovered two series of compounds that are positive modulators at alpha 2-/alpha 3-containing GABA(A) receptors and that show no functional activity at alpha 1-containing GABAA receptors. We report studies to improve this functional selectivity and ultimately deliver clinical candidates. The functional SAR of cinnolines and quinolines that are positive allosteric modulators of the alpha 2- and alpha 3-containing GABA(A) receptors, while simultaneously neutral antagonists at alpha 1-containing GABAA receptors, is described. Such functionally selective modulators of GABA(A) receptors are expected to be useful in the treatment of anxiety and other psychiatric illnesses. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.035
• 作为产物：
  描述：

  氰乙酸乙酯 在 水 作用下， 以 正丙胺 为溶剂， 反应 16.0h， 以to afford 2-cyano-N-propylacetamide as a white solid (11 g, 98%)的产率得到2-氰基-N-丙基乙酰胺
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

  摘要：

  本文介绍了新的杂环化合物和组合物，以及它们作为治疗疾病的药物的应用。还提供了抑制人类或动物主体中PAS激酶（PASK）活性的方法，用于治疗糖尿病等疾病。

  公开号：

  US20120277224A1

文献信息

• IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：SHANDONG LUYE PHARMACEUTICAL CO., LTD.

  公开号：US20190169140A1

  公开（公告）日：2019-06-06

  A compound as an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.

  一种作为吲哌酮胺-2,3-二氧化酶1（IDO1）抑制剂的化合物，以及其在IDO1相关疾病领域中的应用，特别是如公式（I）所示的化合物及其药用可接受的盐。
• Synthesis of resveratrol acrylamides derivatives and biological evaluation of their anti-proliferative effect on cancer cell lines
  作者：Ban-Feng Ruan、Si-Qi Wang、Xiao-Lin Ge、Ri-Sheng Yao

  DOI：10.2174/15701808113109990057

  日期：2013.11

  A new series of resveratrol acrylamides amine derivatives was designed, synthesized, and evaluated for their anti-proliferative activity against three cancer cell lines including human chronic myelocytic leukemia cell K562, human hepatoma HuH-7 and human lung carcinoma A549. Most of the compounds showed superior activity against three cell lines when compared to parent resveratrol. C13 had the best anti-tumor activity against the HuH-7 cell line and its IC50 was 4.5 μmol/L; C16 had the best anti-tumor activity against the K562 cell line and its IC50 was 2.9 μmol/L; C18 had the best anti-tumor activity against the A549 cell line and its IC50 was 3.8 μmol/L. It could be seen that the activity of the aromatic amine derivatives was better than the fatty amine derivatives by analyzing the experimental data.

  设计、合成并评价了一系列白藜芦醇丙烯酰胺胺衍生物对三种癌细胞株的抗增殖活性，包括人慢性髓细胞白血病细胞K562、人肝癌HuH-7和人肺癌A549。与母体白藜芦醇相比，大多数化合物对三种细胞株表现出更强的活性。C13对HuH-7细胞株具有最佳的抗肿瘤活性，其IC50为4.5 μmol/L; C16对K562细胞株具有最佳的抗肿瘤活性，其IC50为2.9 μmol/L；C18对A549细胞株具有最佳的抗肿瘤活性，其IC50为3.8 μmol/L。通过分析实验数据可以发现，芳香胺衍生物的活性优于脂肪胺衍生物。
• [EN] DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS<br/>[FR] DERIVES DE DIHYDROPYRIDINE DESTINES A ETRE UTILISES COMME INHIBITEURS DE L'ELASTASE NEUTROPHILE HUMAINE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004020412A1

  公开（公告）日：2004-03-11

  The invention relates to novel dihydropyridine derivatives, of Formula (I) processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

  这项发明涉及新颖的二氢吡啶衍生物，其化学式为（I），以及它们的制备方法，以及它们在药物中的应用，特别是用于治疗慢性阻塞性肺疾病、急性冠状动脉综合征、急性心肌梗死和心力衰竭的发展。
• Continuous flow synthesis of some 6- and 1,6-substituted 3-cyano-4-methyl-2-pyridones
  作者：Julijana Tadic、Marina Mihajlovic、Mica Jovanovic、Dusan Mijin

  DOI：10.2298/jsc180703092t

  日期：——

  In this paper six 6- and 1,6-substituted-4-methyl-3-cyano-2-pyridones were synthetized in a continuous flow microreactor system. Synthesis was done at room temperature and the obtained results were compared to those achieved within classical synthesis. In order to optimize the continuous flow syntheses and increase the yield of the products, the retention time in the microreactor was varied by changing

  在本文中，在连续流式微反应器系统中合成了6个6-和1,6-取代的-4-甲基-3-氰基-2-吡啶酮。在室温下进行合成，并将获得的结果与经典合成中获得的结果进行比较。为了优化连续流合成并增加产物的产率，通过改变反应物溶液的流速来改变在微反应器中的保留时间。此外，针对在医药和染料工业中商业上重要的4,6-二甲基-3-氰基-2-吡啶酮和6-羟基-4-甲基-3-氰基-2-吡啶酮对反应进行了优化。在不到10分钟的时间内，以约60％的满意产率获得了两种2-吡啶酮。所得化合物的特征在于熔点，FT-IR，1 H NMR和UV-Vis光谱。
• [EN] NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LE RÉCEPTEUR SENSIBLE AU CALCIUM, ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：LEO PHARMA AS

  公开号：WO2010136037A1

  公开（公告）日：2010-12-02

  The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  该发明涉及一种表示为公式I的新型调节钙感受受体（CaSR）的取代环戊烯化合物及其衍生物，该化合物用作药物，用于治疗的化合物，包含该化合物的制药组合物，使用该化合物治疗疾病的方法以及使用该化合物制造药物。